Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
about
Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.Partial HIV C2V3 envelope sequence analysis reveals association of coreceptor tropism, envelope glycosylation and viral genotypic variability among Kenyan patients on HAART.Recombinant subunit vaccines for soil-transmitted helminths.Genetic and structural analyses of affinity maturation in the humoral response to HIV-1.Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem.Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.The HIV-1 envelope glycoprotein structure: nailing down a moving target.Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer.Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies.Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic miceConformational Heterogeneity of the HIV Envelope Glycan Shield.Env-Specific Antibodies in Chronic Infection versus in Vaccination.Molecular basis of human CD22 function and therapeutic targeting.Correction: Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens.Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows.Porcine reproductive and respiratory syndrome virus neutralizing antibodies provide in vivo cross-protection to PRRSV1 and PRRSV2 viral challenge.The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer.Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity.Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodiesThe human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogenDevelopment of broadly neutralizing antibodies in HIV-1 infected elite neutralizersBeyond Hot Spots: Biases in Antibody Somatic Hypermutation and Implications for Vaccine DesignWhen designing vaccines, consider the starting material: the human B cell repertoire
P2860
Q30234773-D33CBC56-7927-4F6E-94FF-AFA47418C7CDQ37246321-51782DA7-EE9F-432E-90B9-993BE3CBD8C5Q37642937-F9785316-F974-4E54-8DBE-C577D654096CQ38647737-58641B5A-C9ED-4013-9DC7-60297364AF2EQ38992744-CC63E854-9720-4E30-9E90-05A65731C6F8Q39108730-5DC1D00D-9133-470F-957B-3887EE9D1834Q39108735-26C5AE27-BDA0-4025-821C-82DB3F79678FQ39108789-944643AE-BD71-4DED-B233-884419FF549AQ40061438-4FE7164D-4D1E-4F1E-8DD1-0B7A45B8C629Q40118226-1448BC92-C878-4647-9C46-FEDD71BF3B4BQ40301176-FCD9FD82-7EE9-43B9-9224-704DC0BD0C05Q40589505-E49B83D4-1301-4C04-A962-D21C450A8055Q40985221-B092477D-DA2B-4861-96B0-BCA0858022F8Q41475637-6D2250B7-4143-4FC4-ACC0-4A2E6F77D8D9Q42286136-36D7533B-D4A0-48A6-98C1-6DE4EA2C0C98Q42395228-0D0A0BB6-F18E-404F-8837-B337369DB658Q46631754-E8162545-3111-4CC8-8411-9648D47104F9Q47232975-FD7C1442-D882-473F-87D1-8402C759D1E2Q47700206-013614E0-79A3-400B-94D2-66221E4F4D2CQ50166841-565F56E3-EFF1-4F36-A2B6-955E242DCB15Q52584646-5A1DAA11-FE05-4325-A2F9-522A7FD43FB7Q54209542-75B1F4DD-77C9-4890-9156-24BE415D11D4Q55265892-5B3A7F03-A4E9-470D-A029-CA05C6457A77Q55356257-AE21C85E-FC51-4BF2-B3B6-662F8B0F28D5Q57003103-25DA2C2A-0802-426F-826A-A11A8A0EB1B1Q57094341-A0BD400D-FDC1-452B-BA73-5461C638398EQ58763247-1DAA10D3-5C5C-46B3-A758-5B38D9BFD669Q58781552-7052C3BA-C5DF-4800-AABC-7FDA28A10E26Q58804243-CD0B37D3-0ABC-4FD2-B526-E88215FB58B6
P2860
Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Minimally Mutated HIV-1 Broadl ...... e Reductionist Vaccine Design.
@ast
Minimally Mutated HIV-1 Broadl ...... e Reductionist Vaccine Design.
@en
type
label
Minimally Mutated HIV-1 Broadl ...... e Reductionist Vaccine Design.
@ast
Minimally Mutated HIV-1 Broadl ...... e Reductionist Vaccine Design.
@en
prefLabel
Minimally Mutated HIV-1 Broadl ...... e Reductionist Vaccine Design.
@ast
Minimally Mutated HIV-1 Broadl ...... e Reductionist Vaccine Design.
@en
P2093
P2860
P50
P1433
P1476
Minimally Mutated HIV-1 Broadl ...... de Reductionist Vaccine Design
@en
P2093
Bryan Briney
Carole J Henry Dunand
Chi-Hui Liang
Denise M Galloway
Dennis R Burton
Devan Diwanji
Erin A Scherer
Ian A Wilson
Joseph G Jardine
P2860
P304
P356
10.1371/JOURNAL.PPAT.1005815
P577
2016-08-25T00:00:00Z